Emerging developments in the forefront of peanut oral immunotherapy

Area of Science:

• Allergy and Immunology
• Food Allergy Research
• Immunotherapy

Background:

• The COVID-19 pandemic impacted clinical practices, including peanut oral immunotherapy (OIT).
• Progress in peanut OIT research continued despite pandemic-related disruptions.
• Clinicians now have access to the first FDA-approved OIT product for peanut allergy.

Purpose of the Study:

• To review recent advancements in peanut oral immunotherapy.
• To highlight the impact of the COVID-19 pandemic on OIT practices.
• To discuss the implications of the first FDA-approved peanut OIT product.

Main Methods:

• Review of recent scientific literature on peanut OIT.
• Analysis of pandemic-induced modifications to OIT practices.
• Synthesis of new findings in OIT pathophysiology and outcomes.

Main Results:

• The US FDA approved the first oral immunotherapy product for peanut allergy in January 2020.
• Pandemic-related practice modifications may have lasting effects on OIT.
• New research has advanced understanding of OIT's impact on pathophysiology, sustained unresponsiveness, quality of life, safety, and cost-effectiveness.

Conclusions:

• The FDA approval marks a significant milestone in treating peanut allergy.
• Further research is necessary to address knowledge gaps regarding optimal peanut OIT utilization.
• Peanut OIT remains a developing field with ongoing research and evolving clinical application.